Drug interactions and bleeding complications with rivaroxaban compared to warfarin
- In: Poster presentation
- At: Seoul (South Korea) (2017)
- Type: Poster
- Poster code: POS-PPR-001
- By: CARDONA, Mark (Attard, Malta)
- Co-author(s): Mark George Cardona
Francesca Wirth
Anthony Serracino-Inglott
Lilian M Azzopardi - Abstract:
Background
Compared to warfarin, the novel oral anticoagulant (NOAC) rivaroxaban has fewer potential drug-drug interactions (DDIs). However, there is conflicting evidence regarding bleeding complications.Purpose
To compare rivaroxaban and warfarin with respect to potential DDIs and incidence and severity of bleeding.Methods
Following ethics
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023